GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Regenix Group PLC (LSE:TRX) » Definitions » Effective Interest Rate on Debt %

Tissue Regenix Group (LSE:TRX) Effective Interest Rate on Debt % : 9.18% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Tissue Regenix Group Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Tissue Regenix Group's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was £0.69 Mil. Tissue Regenix Group's average total debt for the quarter that ended in Dec. 2023 was £7.47 Mil. Therefore, Tissue Regenix Group's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 9.18%.


Tissue Regenix Group Effective Interest Rate on Debt % Historical Data

The historical data trend for Tissue Regenix Group's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Regenix Group Effective Interest Rate on Debt % Chart

Tissue Regenix Group Annual Data
Trend Jan14 Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.86 11.10 9.17 8.77 11.74

Tissue Regenix Group Semi-Annual Data
Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.97 10.09 7.52 14.48 9.18

Competitive Comparison of Tissue Regenix Group's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Tissue Regenix Group's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tissue Regenix Group's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Effective Interest Rate on Debt % falls into.



Tissue Regenix Group Effective Interest Rate on Debt % Calculation

Tissue Regenix Group's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -0.899/( (7.888+7.422)/ 2 )
=-1  *  -0.899/7.655
=11.74 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=6.957 + 0.931
=7.888

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=6.915 + 0.507
=7.422

Tissue Regenix Group's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -0.686/( (7.522+7.422)/ 2 )
=-1  *  -0.686/7.472
=9.18 %

where

Total Debt  (Q: Jun. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=7.211 + 0.311
=7.522

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=6.915 + 0.507
=7.422

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Tissue Regenix Group  (LSE:TRX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Tissue Regenix Group Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Tissue Regenix Group's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tissue Regenix Group (LSE:TRX) Business Description

Industry
Traded in Other Exchanges
Address
Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.